Questions about the 10 x '20 Initiative

Comment

Kevin Outterson et al. Clin Infect Dis. 2010.

. 2010 Sep 15;51(6):751-2; author reply 754-5.

doi: 10.1086/655955.

No abstract available

Comment on

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
Infectious Diseases Society of America. Infectious Diseases Society of America. Clin Infect Dis. 2010 Apr 15;50(8):1081-3. doi: 10.1086/652237. Clin Infect Dis. 2010. PMID: 20214473

Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.
Burgess DS, Slain D, Mohr J, Wong-Beringer A, Destache C, Suda K. Burgess DS, et al. Clin Infect Dis. 2010 Sep 15;51(6):753; author reply 754-5. doi: 10.1086/655957. Clin Infect Dis. 2010. PMID: 20731568 No abstract available.
Development of new antibacterials: a laudable aim, but what is the value?
Tillotson GS. Tillotson GS. Clin Infect Dis. 2010 Sep 15;51(6):752-3; author reply 754-5. doi: 10.1086/655956. Clin Infect Dis. 2010. PMID: 20731567 No abstract available.
Coping with antibiotic resistance: the impending crisis.
Gould IM. Gould IM. Int J Antimicrob Agents. 2010 Nov;36 Suppl 3:S1-2. doi: 10.1016/S0924-8579(10)00497-8. Int J Antimicrob Agents. 2010. PMID: 21129626 Review.
The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
Infectious Diseases Society of America. Infectious Diseases Society of America. Clin Infect Dis. 2010 Apr 15;50(8):1081-3. doi: 10.1086/652237. Clin Infect Dis. 2010. PMID: 20214473
A call for antibiotic alternatives research.
Stanton TB. Stanton TB. Trends Microbiol. 2013 Mar;21(3):111-3. doi: 10.1016/j.tim.2012.11.002. Trends Microbiol. 2013. PMID: 23473628 Review.